Filtered By:
Cancer: Adenocarcinoma
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 766 results found since Jan 2013.
Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells.
In this study, we identified ret finger protein-like 3 (RFPL3) as a hTERT promoter binding protein in lung cancer cells. The high hTERT promoter-binding activity of RFPL3 was detected in lung cancer cells compared to normal cells. Chromatin immunoprecipitation confirmed RFPL3 as a tumor-specific hTERT promoter binding protein. Overexpression of RFPL3 activated hTERT promoter and up-regulated hTERT expression and telomerase activity. Inhibition of RFPL3 expression by siRNA suppressed hTERT promoter activation and telomerase activity. Inhibition of RFPL3 by siRNA or shRNA also significantly inhibited tumor cell growth in vit...
Source: Oncotarget - December 12, 2014 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Claudin 1 mediates tumor necrosis factor alpha-induced cell migration in human gastric cancer cells.
CONCLUSION: These results suggest that claudin 1 is an important messenger that regulates TNF-α-induced gene expression and migration in gastric cancer cells. A deeper understanding of these cellular processes may be helpful in establishing new therapeutic strategies for gastric cancer.
PMID: 25548484 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - December 21, 2014 Category: Gastroenterology Authors: Shiozaki A, Shimizu H, Ichikawa D, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Iitaka D, Nakashima S, Nako Y, Liu M, Otsuji E Tags: World J Gastroenterol Source Type: research
Dickkopf‑3 (Dkk3) induces apoptosis in cisplatin‑resistant lung adenocarcinoma cells via the Wnt/β‑catenin pathway.
In conclusion, the re‑activation of Dkk3 enhances the chemosensitivity to cisplatin in cisplatin‑resistant lung adenocarcinoma cell lines, which requires additional studies to realize this potential in clinical use.
PMID: 25573172 [PubMed - as supplied by publisher]
Source: Oncology Reports - January 16, 2015 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues.
CONCLUSIONS: AGR2 could serve as an adjunctive surrogate protein marker possibly reflecting EGFR gene mutations in lung adenocarcinoma patients. Results from in vitro analysis indicated that AGR2 could be a potential clinical biomarker of EGFR-TKI therapeutic sensitivity in lung adenocarcinoma cells.
PMID: 25634032 [PubMed - as supplied by publisher]
Source: International Journal of Biological Markers - January 31, 2015 Category: Laboratory Medicine Tags: Int J Biol Markers Source Type: research
Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.
Authors: Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu W, Yu W, Dai M, Li Z, Yi C, Zhao S, Li M, Du S, Cheng W, Xiao X, Chen Y, Wu T, Meng S, Yuan Y, Liu Q, Huang W, Guo W, Wang S, Deng W
Abstract
Cyclooxygenase-2 (COX-2) plays an important role in lung cancer development and progression. Using streptavidin-agarose pulldown and proteomics assay, we identified and validated Ku80, a dimer of Ku participating in the repair of broken DNA double strands, as a new binding protein of the COX-2 gene promoter. Overexpression of Ku80 up-regulated COX-2 promoter activation and COX-2 expression in lung cancer cells. Silencing of Ku...
Source: Oncotarget - March 24, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Abstract 110: The role of the p53 target Wig-1 in senescence and cancer
The wild type p53-induced gene 1, Wig-1 (also known as Zmat3 or PAG608) binds to AU-rich elements in mRNAs and thereby regulates important tumor associated factors including p53, FAS, and N-Myc.Focusing on normal human diploid fibroblasts (HDF), we are now exploring the role of Wig-1 in senescence. SiRNA-mediated Wig-1 depletion increases senescence markers such as Beta-galactosidase staining, H3K9me3, H4K20me3, and p21. Also, Wig-1 is spontaneously downregulated in cells undergoing replicative senescence.The trimethylation of lysine 9 on histone 3 (H3K9me3) is an established marker of cellular senescence and increases upo...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Jerhammar, F., Bersani, C., Djureinovic, D., Micke, P., Wiman, K. G. Tags: Molecular and Cellular Biology Source Type: research
Abstract 245: Identification of novel immune checkpoints as potential therapeutic targets in pancreatic ductal adenocarcinoma (PDAC) using RNAi screening
CONCLUSION: We set up a robust and systematic method to identify novel immune checkpoints for pancreatic cancer. Further functional validation of our candidate genes will prove their use as therapeutic targets.Citation Format: Antonio Sorrentino, Tillmann Michels, Ayse Nur Menevse, Nisit Khandelwal, Marco Breinig, Isabel Poschke, Rienk Offringa, Michael Boutros, Philipp Beckhove. Identification of novel immune checkpoints as potential therapeutic targets in pancreatic ductal adenocarcinoma (PDAC) using RNAi screening. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Sorrentino, A., Michels, T., Menevse, A. N., Khandelwal, N., Breinig, M., Poschke, I., Offringa, R., Boutros, M., Beckhove, P. Tags: Immunology Source Type: research
Abstract 696: Comprehensive genomic analysis identifies frequent MET juxtamembrane domain deletions as an actionable genomic alteration in pulmonary sacromatoid carcinoma
Conclusions:Our study finds an unprecedently high frequency of exon 14 skipping MET mutations in pulmonary SC and suggests that MET activation might contribute to the mesenchymal differentiation and aggressive biology and defines MET inhibition as a promising novel therapeutic strategy for MET-mutated pulmonary SC.Citation Format: Xuewen Liu, Yuxia Jia, Yufeng Shen, Haiying Cheng, Sanjay Koul, Alain C. Borczuk, Balazs Halmos. Comprehensive genomic analysis identifies frequent MET juxtamembrane domain deletions as an actionable genomic alteration in pulmonary sacromatoid carcinoma. [abstract]. In: Proceedings of the 106th A...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Liu, X., Jia, Y., Shen, Y., Cheng, H., Koul, S., Borczuk, A. C., Halmos, B. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1191: The RNA binding protein, HuR, regulates pancreatic cancer cell metabolism
Conclusions: HuR enhances metabolic efficiency in PDA cells by directly regulating multiple metabolic pathways. Ongoing microarray studies will highlight which metabolic transcripts are post-transcriptionally regulated by HuR, resulting in the observed phenotype.canres;75/15_Supplement/1191/table1T1Altered metabolites due to HuR silencing in PDA cells ([1,2-13C2]-D-glucose tracer)PathwayMetabolitesiHuR 25mM glucosesiHuR 5 mM glucoseCorrelation1Myristate (C:14) Intracell13C enrichment70.271.01.02Myristate (C:14) intracellFNS (direct)56.060.41.03Oleate (C:18-1) IntracellIndirect synthes-m187.689.51.04Glutam extracell [C2-C5]...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Blanco, F. F., Zarei, M., Brody, J. R., Boros, L. G., Winter, J. M. Tags: Molecular and Cellular Biology Source Type: research
Abstract 1434: MDM2 promotes tumor cell migration through the induction of epithelial to mesenchymal transition
Conclusion: In summary, this study explored the molecular mechanisms underlying the role of MDM2 in cancer progression. MDM2 expression has been demonstrated to be closely correlated to human ovarian adenocarcinoma clinical staging, indicating the possible utilization of MDM2 in prognosis. Further study clarified MDM2 promoted tumor cell migration through the induction of EMT, which provides new theoretical evidences for the roles that MDM2 plays in tumor metastasis. Our study implicates that MDM2 may be a potential target for inhibiting metastasis and contributes to the translational research of MDM2 inhibitors as anti-me...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Zheng, L., Wu, Y., Zhou, T., Zhu, H., He, Q., Yang, B. Tags: Tumor Biology Source Type: research
Abstract 3613: P300 inhibition enhances cytotoxic effect of Gemcitabine through E2F1 activation in pancreatic cancer
Background:Transcriptional cofactor, P300 has been reported to regulate cell cycle on G1/S transition. Previously, we shown that prolonged S-phase is associated with increased apoptosis induced by Gemcitabine (GEM) in pancreatic cancer cells. Thus, we hypothesized that targeting P300 enhances the cytotoxic effect of GEM on pancreatic cancer.Methods:We studied 2 human pancreatic cancer cell lines, Panc1 and MIAPaCa2. P300 was gene-silenced using siRNA, and P300 histone acetyltransferase (HAT) activity was inhibited by specific inhibitor C646. Cell viability was measured by WST-8 assay and GEM-induced apoptosis was measured ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ono, H., Basson, M. D., Ito, H. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3616: Development of a Sox2 targeting therapy for the treatment of lung squamous cell carcinoma
Despite the recent development of several effective molecular targeted agents, lung cancer is the most common cause of cancer related deaths worldwide. Recently, molecular targeted therapies for pulmonary adenocarcinoma with mutant EGFR or ALK fusions have reduced non-tumor toxicity and have extended patient survival time compared to conventional chemotherapies. However, the development of molecular targeting drugs for NSCLC has made apparent the fact that histology is an important factor and molecularly targeted therapies have been more effective in pulmonary adenocarcinoma than in lung squamous cell carcinoma. Therefore,...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ishida, N., Fukazawa, T., Takaoka, M., Yamatsuji, T., Morita, I., Haisa, M., Takaoka, N., Naomoto, Y. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 4440: The functional role of insulin-like growth factor binding protein-2 in esophageal adenocarcinoma chemoresistance
Despite improved understanding of esophageal adenocarcinoma (EAC) progression and advances in endoscopic surveillance and multimodality treatment, patients commonly present with advanced stage disease and demonstrate resistance to therapy, with complete response rates below 40%. Understanding the molecular mechanisms of resistance is crucial for predicting and overcoming this resistance.IGFBP2 is a member of the IGFBP family of proteins that has been shown to modulate both insulin growth factor (IGF) and integrin signaling and is a mediator of cell growth, invasion and resistance in other tumor types. Because these pathway...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Myers, A. L., Lin, L., Nancarrow, D. J., Wang, Z., Ferrer-Torres, D., Beer, D. G., Chang, A. C. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 4690: Next-generation screen for integrative subtyping and target discovery for KRAS-mutant cancer
Mutations in the small GTPase, KRAS, are found in ∼140,000 new cases of cancer every year in the United States. This heterogeneous class of cancers manifests primarily as adenocarcinomas of the lung, colon and pancreas. These cancers display a wide spectrum of KRAS-dependency and differentially activate downstream effector signaling. The tumors further diverge in their array of co-occurring secondary mutations, expression signatures and KRAS mutant allele. Ultimately, the sole trait these cancers share in common is an obstinate resistance to chemo- and targeted-therapies, making identification of effective treatments an ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Yuan, T. L., Bagni, R., Yi, M., Amzallag, A., Afghani, S., Beam, K., Burgan, W., Fer, N., Garvey, L., Smith, B., Waters, A., Stephens, R., Benes, C., McCormick, F. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 5113: Rapid Cancer Imaging By GGT-targeted Fluorescence Probe For Primary Lung Cancer
IntroductionLung cancer is the leading cause of cancer death in Japan, however, it has been difficult to detect and diagnose precisely lung cancer with a diameter less than 1cm to date. The purpose of this study is to investigate clinical application of novel GGT-targeted fluorescence probe for detecting the primary lung cancer in an intraoperative manner.MethodsAs a fluorescence probe for γ-glutamyltranspeptidase (GGT), γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG) was used. gGlu-HMRG is non-fluorescent, but is converted to a highly fluorescent hydroxymethyl rhodamine green (HMRG) upon reaction with the enzyme, w...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Hino, H., Kawashima, M., Murayama, T., Ichinose, J., Kitano, K., Nagayama, K., Nitadori, J.-i., Anraku, M., Murakawa, T., Mizuno, K., Tanaka, S., Kamiya, M., Nishiyama, N., Kataoka, K., Miyazono, K., Urano, Y., Nakajima, J. Tags: Tumor Biology Source Type: research
